Structure and properties
Remogliflozin (C23H32N2O8, Mr = 464.5 g/mol) is present in drugs as remogliflozinetabonate, an ester prodrug of remogliflozin.
Effects
Remogliflozin has antidiabetic and antihyperglycemic properties. It is a selective inhibitor of sodium–glucose co-transporter 2 (SGLT2). This transporter is responsible for the reabsorption of glucose at the proximal tubule of the nephron. Inhibition leads to increased excretion of the sugar via the urine. The mechanism of action is independent of insulin, unlike other antidiabetic agents. Remogliflozin is specific for SGLT2 and does not inhibit SGLT1, which is responsible for glucose absorption in the intestine.
Indications
For the treatment of type 2 diabetes.